Tyrosine kinase receptor inhibitor as a molecularly targeted therapy for solid tumors
Advances in solid tumor treatment have been enormous in the past decade, especially molecularly targeted therapy, for which aberrant molecules or biological pathways relating to tumor growth and development have been targeted specifically. Molecularly targeted therapy agents show activity against sp...
Main Author: | P Sunpaweravong |
---|---|
Format: | Article |
Language: | English |
Published: |
Prince of Songkla University
2006-01-01
|
Series: | Journal of Health Science and Medical Research (JHSMR) |
Subjects: | |
Online Access: | https://www.jhsmr.org/index.php/jhsmr/article/view/557 |
Similar Items
-
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
by: Andrew J. Bellantoni, et al.
Published: (2021-07-01) -
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
by: Liling Huang, et al.
Published: (2020-10-01) -
Receptor Tyrosine Kinase-Targeted Cancer Therapy
by: Toshimitsu Yamaoka, et al.
Published: (2018-11-01) -
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
by: D. Samuel Metibemu, et al.
Published: (2019-12-01) -
Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
by: Maria Krchniakova, et al.
Published: (2022-09-01)